Skip to content
  • Debatforum
  • Seneste
  • Populære
  • Bruger
Temaer
  • Light
  • Dark

Kollaps
FORSIDEN
Log ind Opret konto

Genmab — Maj 2019

Planlagt Fastgjort Låst Flyttet Genmab
2.0k Indlæg 1 Posters 0 Visninger
  • Ældste til nyeste
  • Nyeste til ældste
  • Most Votes
Svar
  • Svar som emne
Login for at svare
Denne tråd er blevet slettet. Kun brugere med emne behandlings privilegier kan se den.
  • bongobobB Offline
    bongobobB Offline
    bongobob
    wrote on sidst redigeret af
    #1219

    Nu har de jo fordoblet medarbejder antallet, mon ikke der er en af de nye der har styr på det

    1 Reply Last reply
    0
    • P Offline
      P Offline
      Parasitism
      wrote on sidst redigeret af
      #1220

      God morgen 🙂

      1 Reply Last reply
      0
      • B Offline
        B Offline
        bibob
        wrote on sidst redigeret af
        #1221

        God morgen. 🙂

        1 Reply Last reply
        0
        • Helge_LarsenPI-redaktørH Offline
          Helge_LarsenPI-redaktørH Offline
          Helge_LarsenPI-redaktør
          wrote on sidst redigeret af
          #1222

          Der er ikke meget andet end mine Genmab som er i plus lige nu.

          1 Reply Last reply
          0
          • P Offline
            P Offline
            polle1
            wrote on sidst redigeret af
            #1223

            Det er da meget rart, at det for én gangs skyld vender på den måde 🙂

            1 Reply Last reply
            0
            • J Offline
              J Offline
              Jazzz
              wrote on sidst redigeret af
              #1224

              Ja udover et par få lyspunkter er det en temmeligt trist affære i disse uger..

              1 Reply Last reply
              0
              • S Offline
                S Offline
                Sukkeralf
                wrote on sidst redigeret af
                #1225

                Link Preview Image
                Novartis har 25 blockbustere i pipelinen og milliarder på vej til Genmab

                Den schweiziske life science-kæmpe Novartis har 25 lægemiddelkandidater i sin pipeline med potentiale til at sælge for mere end 1 mia. dollar årligt, vurderer ledelsen. Blandt dem finder man en kandidat udviklet af Genmab, som kan give det danske biotekselskab årlige betalinger på over 1 mia. kr., hvis forudsigelserne holder stik.

                favicon

                (medwatch.dk)

                1 Reply Last reply
                0
                • V Offline
                  V Offline
                  Vitus
                  wrote on sidst redigeret af
                  #1226

                  Det var da bestemt ikk
                  e en trist oplysning sukkeralf

                  1 Reply Last reply
                  0
                  • Helge_LarsenPI-redaktørH Offline
                    Helge_LarsenPI-redaktørH Offline
                    Helge_LarsenPI-redaktør
                    wrote on sidst redigeret af
                    #1227

                    News flowet har vendt til det positive.

                    1 Reply Last reply
                    0
                    • J Offline
                      J Offline
                      JKY_VH
                      wrote on sidst redigeret af
                      #1228

                      elsker den slags overskrifter Sukkeralf:-)

                      1 Reply Last reply
                      0
                      • Helge_LarsenPI-redaktørH Offline
                        Helge_LarsenPI-redaktørH Offline
                        Helge_LarsenPI-redaktør
                        wrote on sidst redigeret af
                        #1229

                        Det er god suppe på et gammelt ben. 🙂

                        1 Reply Last reply
                        0
                        • BulderB Offline
                          BulderB Offline
                          Bulder
                          wrote on sidst redigeret af
                          #1230

                          det er jo lige før vi får Asclepios-data før Maia-godkendelse.

                          1 Reply Last reply
                          0
                          • E Offline
                            E Offline
                            E_L
                            wrote on sidst redigeret af
                            #1231

                            another Novartis article https://endpts.com/one-of-the-worlds-top-rd-spenders-wants-you-to-see-what-9b-a-year-gets-you/

                            1 Reply Last reply
                            0
                            • E Offline
                              E Offline
                              E_L
                              wrote on sidst redigeret af
                              #1232

                              and here you can download the presentation slides https://www.novartis.com/investors/event-calendar

                              1 Reply Last reply
                              0
                              • E Offline
                                E Offline
                                E_L
                                wrote on sidst redigeret af
                                #1233

                                301 Moved Permanently

                                favicon

                                (www.evaluate.com)

                                1 Reply Last reply
                                0
                                • E Offline
                                  E Offline
                                  E_L
                                  wrote on sidst redigeret af
                                  #1234

                                  Doctor survey suggests 'rapid uptake' for Horizon's teprotumumab, says Jefferies Jefferies analyst David Steinberg says his survey of 25 high-volume physicians regarding the treatment landscape for thyroid eye disease indicates the potential for rapid uptake of Horizon Pharma's teprotumumab.

                                  1 Reply Last reply
                                  0
                                  • E Offline
                                    E Offline
                                    E_L
                                    wrote on sidst redigeret af
                                    #1235

                                    The responses suggest not only high unmet need for this rare condition but also a "unanimous view" that teprotumumab is disease modifying, Steinberg tells investors in a research note. He believes the antibody could be priced at a premium to his $100,000 per treatment forecast, assuming approval in the first half of 2020. Steinberg keeps a Buy rating on Horizon Pharma with a $34 price targe
                                    https://thefly.com/landingPageNews.php?id=2913164

                                    1 Reply Last reply
                                    0
                                    • E Offline
                                      E Offline
                                      E_L
                                      wrote on sidst redigeret af
                                      #1236

                                      Enapotamab Vedotin (HuMax-AXL-ADC) trial enlarged from 292 to 374 patients (extra cohorts being added i assume, as expected) https://clinicaltrials.gov/ct2/history/NCT02988817?A=12&B=13&C=merged#StudyPageTop

                                      1 Reply Last reply
                                      0
                                      • troldmandenT Offline
                                        troldmandenT Offline
                                        troldmanden
                                        wrote on sidst redigeret af
                                        #1237

                                        Was this expected? Thats about 80 DKK more to run this ekstra cohort

                                        1 Reply Last reply
                                        0
                                        • troldmandenT Offline
                                          troldmandenT Offline
                                          troldmanden
                                          wrote on sidst redigeret af
                                          #1238

                                          80 mill DKK 🙂

                                          1 Reply Last reply
                                          0

                                          Hello! It looks like you're interested in this conversation, but you don't have an account yet.

                                          Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.

                                          With your input, this post could be even better 💗

                                          Tilmeld Log ind

                                          • Log ind

                                          • Har du ikke en konto? Tilmeld

                                          • Login or register to search.
                                          • First post
                                            Last post
                                          0
                                          • Debatforum
                                          • Seneste
                                          • Populære
                                          • Bruger